Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab modified treat-and-extend regimen in macular edema secondary to CRVO/HRVO
jRCTs041250001Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of faricimab in central retinal vein occlusion (CRVO) and central retinal vein occlusion with macular edema, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in best corrected visual acuity (BCVA) at Week 72. Started Jul 2025; status: active, not recruiting.
02
Drugs
faricimab
03
Conditions
central retinal vein occlusion (CRVO)central retinal vein occlusion with macular edema
Beyond the preview
Go deeper on jRCTs041250001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041250001.